Medicxi Announces €500 Million Fund V

Medicxi raises €500m for fifth biotech fund

Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+

Medicxi Announces €500 Million Fund V

/PRNewswire/ -- Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to...

Medicxi closes fifth fund to back ‘asset-centric’ startups

The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of recent buyout deals involving portfolio companies like Merus and Vicebio.

Medicxi, which backed Vicebio and Versanis, closes new €500M biotech fund

London-based VC firm Medicxi has secured €500 million ($581 million) for a new fund dedicated to biotech creation and some “opportunistic” later-stage investments that could transform patient care.

Asset-focused biotech investor Medicxi seals biggest fundraise yet by closing €500m Fund V

European life sciences investor Medicxi has closed its latest flagship venture capital fund on €500m, marking its biggest raise yet. The post Asset-focused biotech investor Medicxi seals biggest fundraise yet by closing €500m Fund V appeared first on AltAssets Private Equity News.

Medicxi Raises €500 Million for Fifth Fund to Support Asset-Centric Biotech Startups

Medicxi, a European venture capital firm, has successfu […] The post Medicxi Raises €500 Million for Fifth Fund to Support Asset-Centric Biotech Startups first appeared on GeneOnline News. The post Medicxi Raises €500 Million for Fifth Fund to Support Asset-Centric Biotech Startups appeared first on GeneOnline News.